Second, afatinib did not show a significant antitumor effect in NSCLC patients with the EGFR K860I mutation, despite afatinib having an antitumor effect on the K860I missense mutation in vitro.20 The gene discussed is EGFR; the disease is non-small cell lung carcinoma.